TruAlt Bioenergy shares slipped 6.7% in two sessions after listing, as early investors booked profits. Despite strong FY25 growth—54% revenue rise, fivefold net profit surge—valuations remain steep at 29x earnings. Analysts suggest partial profit booking amid robust renewable energy demand.
